Cargando…
Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome
In addition to mutations in genes, aberrant enhancer element activity at non-coding regions of the genome is a key driver of tumorigenesis. Here, we perform epigenomic enhancer profiling of a cohort of more than forty genetically diverse human colorectal cancer (CRC) specimens. Using normal colonic...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309719/ https://www.ncbi.nlm.nih.gov/pubmed/28169291 http://dx.doi.org/10.1038/ncomms14400 |
_version_ | 1782507755507023872 |
---|---|
author | Cohen, Andrea J. Saiakhova, Alina Corradin, Olivia Luppino, Jennifer M. Lovrenert, Katreya Bartels, Cynthia F. Morrow, James J. Mack, Stephen C. Dhillon, Gursimran Beard, Lydia Myeroff, Lois Kalady, Matthew F. Willis, Joseph Bradner, James E. Keri, Ruth A. Berger, Nathan A. Pruett-Miller, Shondra M. Markowitz, Sanford D. Scacheri, Peter C. |
author_facet | Cohen, Andrea J. Saiakhova, Alina Corradin, Olivia Luppino, Jennifer M. Lovrenert, Katreya Bartels, Cynthia F. Morrow, James J. Mack, Stephen C. Dhillon, Gursimran Beard, Lydia Myeroff, Lois Kalady, Matthew F. Willis, Joseph Bradner, James E. Keri, Ruth A. Berger, Nathan A. Pruett-Miller, Shondra M. Markowitz, Sanford D. Scacheri, Peter C. |
author_sort | Cohen, Andrea J. |
collection | PubMed |
description | In addition to mutations in genes, aberrant enhancer element activity at non-coding regions of the genome is a key driver of tumorigenesis. Here, we perform epigenomic enhancer profiling of a cohort of more than forty genetically diverse human colorectal cancer (CRC) specimens. Using normal colonic crypt epithelium as a comparator, we identify enhancers with recurrently gained or lost activity across CRC specimens. Of the enhancers highly recurrently activated in CRC, most are constituents of super enhancers, are occupied by AP-1 and cohesin complex members, and originate from primed chromatin. Many activate known oncogenes, and CRC growth can be mitigated through pharmacologic inhibition or genome editing of these loci. Nearly half of all GWAS CRC risk loci co-localize to recurrently activated enhancers. These findings indicate that the CRC epigenome is defined by highly recurrent epigenetic alterations at enhancers which activate a common, aberrant transcriptional programme critical for CRC growth and survival. |
format | Online Article Text |
id | pubmed-5309719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53097192017-02-27 Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome Cohen, Andrea J. Saiakhova, Alina Corradin, Olivia Luppino, Jennifer M. Lovrenert, Katreya Bartels, Cynthia F. Morrow, James J. Mack, Stephen C. Dhillon, Gursimran Beard, Lydia Myeroff, Lois Kalady, Matthew F. Willis, Joseph Bradner, James E. Keri, Ruth A. Berger, Nathan A. Pruett-Miller, Shondra M. Markowitz, Sanford D. Scacheri, Peter C. Nat Commun Article In addition to mutations in genes, aberrant enhancer element activity at non-coding regions of the genome is a key driver of tumorigenesis. Here, we perform epigenomic enhancer profiling of a cohort of more than forty genetically diverse human colorectal cancer (CRC) specimens. Using normal colonic crypt epithelium as a comparator, we identify enhancers with recurrently gained or lost activity across CRC specimens. Of the enhancers highly recurrently activated in CRC, most are constituents of super enhancers, are occupied by AP-1 and cohesin complex members, and originate from primed chromatin. Many activate known oncogenes, and CRC growth can be mitigated through pharmacologic inhibition or genome editing of these loci. Nearly half of all GWAS CRC risk loci co-localize to recurrently activated enhancers. These findings indicate that the CRC epigenome is defined by highly recurrent epigenetic alterations at enhancers which activate a common, aberrant transcriptional programme critical for CRC growth and survival. Nature Publishing Group 2017-02-07 /pmc/articles/PMC5309719/ /pubmed/28169291 http://dx.doi.org/10.1038/ncomms14400 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Cohen, Andrea J. Saiakhova, Alina Corradin, Olivia Luppino, Jennifer M. Lovrenert, Katreya Bartels, Cynthia F. Morrow, James J. Mack, Stephen C. Dhillon, Gursimran Beard, Lydia Myeroff, Lois Kalady, Matthew F. Willis, Joseph Bradner, James E. Keri, Ruth A. Berger, Nathan A. Pruett-Miller, Shondra M. Markowitz, Sanford D. Scacheri, Peter C. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome |
title | Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome |
title_full | Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome |
title_fullStr | Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome |
title_full_unstemmed | Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome |
title_short | Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome |
title_sort | hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309719/ https://www.ncbi.nlm.nih.gov/pubmed/28169291 http://dx.doi.org/10.1038/ncomms14400 |
work_keys_str_mv | AT cohenandreaj hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT saiakhovaalina hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT corradinolivia hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT luppinojenniferm hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT lovrenertkatreya hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT bartelscynthiaf hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT morrowjamesj hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT mackstephenc hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT dhillongursimran hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT beardlydia hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT myerofflois hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT kaladymatthewf hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT willisjoseph hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT bradnerjamese hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT kerirutha hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT bergernathana hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT pruettmillershondram hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT markowitzsanfordd hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome AT scacheripeterc hotspotsofaberrantenhanceractivitypunctuatethecolorectalcancerepigenome |